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Abstract
Background: Escherichia coli isolates of equine faecal origin were investigated for antibiotic resistance, resistance 
genes and their ability to perform horizontal transfer.
Methods: In total, 264 faecal samples were collected from 138 horses in hospital and community livery premises in 
northwest England, yielding 296 resistant E. coli isolates. Isolates were tested for susceptibility to antimicrobial drugs by 
disc diffusion and agar dilution methods in order to determine minimum inhibitory concentrations (MIC). PCR 
amplification was used to detect genes conferring resistance to: ampicillin (TEM and SHV beta-lactamase), 
chloramphenicol (catI, catII, catIII and cml), tetracycline (tetA, tetB, tetC, tetD, tet E and tetG), and trimethoprim (dfrA1, 
dfrA9, dfrA12, dfrA13, dfr7, and dfr17).
Results: The proportion of antibiotic resistant isolates, and multidrug resistant isolates (MDR) was significantly higher in 
hospital samples compared to livery samples (MDR: 48% of hospital isolates; 12% of livery isolates, p < 0.001). 
Resistance to ciprofloxacin and florfenicol were identified mostly within the MDR phenotypes. Resistance genes 
included dfr, TEM beta-lactamase, tet and cat, conferring resistance to trimethoprim, ampicillin, tetracycline and 
chloramphenicol, respectively. Within each antimicrobial resistance group, these genes occurred at frequencies of 93% 
(260/279), 91%, 86.8% and 73.5%, respectively; with 115/296 (38.8%) found to be MDR isolates. Conjugation 
experiments were performed on selected isolates and MDR phenotypes were readily transferred.
Conclusions: Our findings demonstrate that E. coli of equine faecal origin are commonly resistant to antibiotics used in 
human and veterinary medicine. Furthermore, our results suggest that most antibiotic resistance observed in equine E. 
coli is encoded by well-known and well-characterized resistant genes common to E. coli from man and domestic 
animals. These data support the ongoing concern about antimicrobial resistance, MDR, antimicrobial use in veterinary 
medicine and the zoonotic risk that horses could potentially pose to public health.
Introduction
Bacterial resistance to antimicrobials is a global problem,
and understanding the molecular basis of resistance
acquisition and transmission can contribute to the devel-
opment of new strategies to combat this phenomenon.
Furthermore, a zoonotic component to bacterial antimi-
crobial resistance has been demonstrated [1-3]. Horses
can be a reservoir of antibiotic resistant organisms and
genetic determinants of resistance, that may affect veteri-
nary treatment of animals, affect welfare and have eco-
nomic implications. Such resistance can persist even
without selective pressure [1]. Furthermore, antimicro-
bial use in animals can select for resistance genes that
subsequently pose a risk to human public health through
compromising the ability to treat infections [2-5]. The use
of common antimicrobials in equine veterinary practices,
the close contact between humans and horses, along with
the risks and consequences such practices place on
human health and therapy needs to be reassessed.
Commensal E. coli strains from humans and animals
have been reported to express high resistance to common
antimicrobial agents, harbouring antibiotic resistance
genes such as dfrA17 and dfrA12 [6]. These resistance
genes are commonly present on mobile genetic elements
such as plasmids and integrons in clinical isolates of
Gram-negative microorganisms [4]. Furthermore, resis-
tance genes selected for in non-pathogenic bacteria may
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rial species [7,8]. Thus, normal bacterial flora can play a
key role as an acceptor and donor of antimicrobial resis-
tance [9]. It has been suggested that in the UK, antibiotic
resistance in E. coli of animal origin may arise by acquisi-
tion of resistance genes present in MDR bacteria in farm
soil. Thus, these bacteria could play an important role in
the dissemination of antimicrobial resistance genes to
other soil microbes and gastrointestinal bacteria of graz-
ing animals [10].
Whilst several studies in different animals including
horses have analysed E. coli for their susceptibility to anti-
microbial agents and genetic determinants [1,9,11,12],
zoonotic components of antimicrobial resistance varies
between countries [13] and studies of Enterobacteriaceae
of equine origin in the UK are limited. To investigate fac-
tors that may influence zoonotic transmission of antibi-
otic resistant E. coli through faecal shedding by
hospitalized and non-hospitalized horses we describe the
prevalence and mechanisms of antibiotic resistance in E.
coli isolated from equine faecal samples and analysed by
susceptibility testing, PCR analysis and conjugation
experiments.
Methods
Source of isolates
Faecal samples were collected over a six month period
from an equine veterinary hospital and from two livery
stables on the Wirral Peninsula, in north-west England. A
total of 264 faecal samples were collected from 138
horses; 109 of these faecal samples (from 66 horses) came
from the Philip Leverhulme Equine Hospital (PLEH) at
the University of Liverpool and 155 faecal samples (from
72 horses) were randomly sampled at livery yards, com-
prising on average two faecal samples per horse. When
scoring for the presence or absence of antibiotic resistant
E. coli, faecal samples were taken as the unit of analysis.
To investigate the antibiotic resistance profiles of E. coli
shed in faecal samples, three E. coli colonies were isolated
at random from each sample using semi-selective media
(brilliant green broth and eosin methylene blue agar) and
further confirmed biochemically using Api20E
(bioMerieux) test.
Antimicrobial Susceptibility testing
Antimicrobial susceptibility testing was performed using
both disc diffusion and agar dilution methods, according
to the British Society for Antimicrobial Chemotherapy
BSAC guidelines.
Disc diffusion method
Isolates were then subjected to disc diffusion testing
according to the British Society for Antimicrobial Che-
motherapy (BSAC) guidelines as described [14]. All faecal
E. coli isolates resistant to at least one antimicrobial agent
were stored at-80°C, until further analysis. Isolates were
tested for resistance to the following antibiotics: ampicil-
lin (30 μg) (and to cefotaxime (30 μg) and ceftazidime (30
μg) for extended resistance to cephalosporines and
referred in this paper as potential ESBL producers for
ampicillin resistant isolates), apramycin (30 μg), chloram-
phenicol (30 μg) (and to florfenicol (30 μg) for chloram-
phenicol resistant isolates), nalidixic acid (30 μg) (and
ciprofloxacin(1 μg) for nalidixic acid resistant isolates),
tetracycline (30 μg), trimethoprim (2.5 μg), streptomycin
(10 μg), spectinomycin (25 μg), sulphonamides (100 μg)
and gentamicin (10 μg). Stringent criteria were adopted
for defining multidrug drug resistance (MDR), including
resistance to at least four classes of antimicrobial agents.
Extended resistance to cephalosporins was provisionally
assigned following BSAC recommendations and these
strains thereafter referred to as potential ESBL producers.
To determine florfenicol resistance in chloramphenicol
resistant isolates we adopted a criterion of R ≤ 18 mm and
R ≤ 13 mm for apramycin resistance, following personal
communication with J. M. Andrews, BSAC.
Minimum inhibitory concentration (MIC) determination 
using agar dilution method
The MICs of resistant E. coli isolates were determined for
each of the following antibiotics: ampicillin, chloram-
phenicol, ciprofloxacin, tetracycline and trimethoprim
using the agar dilution method as described previously
[15], and evaluated according to BSAC guidelines.
Identification of antibiotic resistance genes
PCR amplification was used to identify genes responsible
for resistance to: ampicillin, chloramphenicol, trimethop-
rim and tetracycline. In total, six different PCR protocols
were applied and 18 antibiotic resistant genes were inves-
tigated. The method for DNA extraction was adapted
from a method described by Kimata et al. [16]. Six PCR
protocols were applied to detect specific genes according
to the resistance phenotype, as follows: TEM and SHV β-
lactamase genes for isolates exhibiting ampicillin resis-
tance [17]; catI, catII, catIII, [18] and cmlA [19] for
chloramphenicol resistance; tetA, tetB, tetC, tetD, tetE
and tetG for six genes responsible for tetracycline resis-
tance [20];dfrA1, dfrA9 [21] and dfrA12, dfrA13, dfrA7,
dfrA17 [22] for trimethoprim resistance genes. PCR
products of dfrA7 and dfrA17, dfrA12 and dfrA13 were
cleaved using 20 U EcoRV and pst1 (Sigma) respectively.
Positive controls were laboratory strains 7071 (dfr12) and
7082a (dfr17). Positive controls for the other resistance
genes were DNA samples from bacterial isolates previ-
ously characterized and sequenced in-house. Table 1 lists
all primer pairs used.
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Conjugation experiments were carried out on isolates
susceptible to nalidixic acid and resistant to ampicillin (n
= 35), using the nalidixic acid resistant E. coli K12 (devel-
oped using E. coli NTCC 10536) as a recipient strain. E.
coli K12 was inoculated into 20 ml nutrient broths
(LabM) and incubated overnight at 37°C. Resistant E. coli
strains (donor strains) were inoculated into separate 3 ml
nutrient broths and incubated overnight; 4 ml of recipi-
ent strain was then added to the donor strain and incu-
bated at 37°C for one hour. Broths were then streaked
onto agar plates containing nalidixic acid (30 μg/ml) plus
ampicillin (8 μg/ml). Plates were incubated for 24 hours.
Successful transconjugants were subcultured onto nutri-
ent agar for susceptibility testing by disc diffusion as pre-
viously described. The resistance profiles of the
transconjugants were compared to the resistance profile
of the original strains. Gene profiles of the donor isolates,
characterized by PCR, were described prior to the tran-
conjugation experiments
Statistical analysis
Data was analysed with SPSS statistical software, using
the z test for comparing two proportions.
Results
Antibiotic resistant E. coli isolates were obtained from
both sources of faeces, but with a significant difference in
the prevalence of resistant isolates between the hospital
and livery premises. For an overview of the frequency of
antibiotic resistant faecal E. coli, comparison was made at
the level of the faecal sample, the unit probably most
closely associated with zoonotic transmission. Among
samples from the hospitalized horses, 89/109 contained
at least one antibiotic-resistant E. coli isolate, whereas
only 38/155 of the livery-derived equine samples con-
tained resistant isolates, (p < 0.001). A collection of 296
antibiotic resistant E. coli isolates, consisting of 219 and
77 resistant isolates from the hospital and livery premises
respectively, were selected for further analysis, allowing
comparison of resistance phenotypes (including MDR) in
individual isolates (summarised in Table 2). The propor-
tion of MDR resistant isolates, identified by disk diffu-
sion, was significantly greater in the hospital-derived
isolates (106/219; 48%) than in livery-derived isolates (9/
77; 12%, p < 0.001). MIC testing confirmed these resis-
tance phenotypes in >90% of the isolates.
Antimicrobial resistance and multidrug resistant (MDR) E. 
coli
The number of isolates showing resistance to each anti-
microbial agent were: trimethorpim (n = 279), tetracy-
cline (n = 198), ampicillin (n = 191), potential ESBLs (n =
17), chloramphenicol (n = 102), florfenicol (n = 14), nali-
dixic acid (n = 72), ciprofloxacin (n = 65), apramycin (n =
1), aminoglycosides (n = 249), sulphonamides (n = 282)
and gentamicin (n = 59) (Table 2). Results obtained
through MIC testing were in good agreement (>93%)
with those obtained by the disc diffusion test (Table 2).
Overall, 115 (38.8%) isolates demonstrated an MDR
phenotype (resistance to four or more classes of antibiot-
ics): 106 MDR isolates were of hospital origin and nine
Table 1: Details of the primers used for PCR protocols.
Primers sequences 5' to 3' amplicon 
size (bp)
Shv: CACTCAAGGATGTATTGTG, 
TTAGCGTTGCCAGTGC
885
Tem: TCGGGGAAATGTGCGCG, 
TGCTTAATCGTGAGGCACC
971
CatI: AGTTGCTCAATGTACCTATAACC, 
TTGTAATTCATTAAGCATTCTGCC
585
CatII: ACACTTTGCCCTTTATCGTC, 
TGAAAGCCATCACATACTGC
495
CatIII: TTCGCCGTGAGCATTTTG, 
TCGGATGAGTATGGGCAAC
508
cmlA: CCGCCACGGTGTTGTTGTTATC, 
CACCTTGCCTGCCCATCATTAG
698
tetB: TTGGTTAGGGGCAAGTTTTG, 
GTAATGGGCCAATAACACCG
659
tetC: CTTGAGAGCCTTCAACCCAG, 
ATGGTCCTCATCTACCTGCC
418
tetD: AAACCATTACGGCATTCTGC, 
GACCGGATACACCATCCATC
787
tetA: GCTACATCCTGCTTGCCTTC, 
CATAGATCGCCGTGAAGAGG
210
tetE: AAACCACATCCTCCATACGC, 
AAATAGGCCACAACCGTCAG
278
tetG: GCTCGGTGGTATCTCTGCTC, 
AGCAACAGAATCGGGAACAC
210
dfr1: ACGGATCCTGGCTGTTGGTTGGACGC, 
CGGAATTCACCTTCCGGCTCGATGTC
254
dfr9: ATGAATTCCCGTGGCATGAACCAGAAGAT, 
ATGGATCCTTCAGTAATGGTCGGGACCTC
399
dfrA7, dfrA17: GTCGCCCTAAAACAAAGTTA, 
CGCCCATAGAGTCAAATGT
195
dfr12, dfr13: CCGTGGGTCGATGTTTGATG, 
GCATTGGGAAGAAGGCGTTCAC
485
Primer sequences and amplification protocols were taken from the 
following sources:: TEM & SHV β-lactamase genes [17];catI, catII, catIII 
[18]; cmlA [19];tetA, tetB, tetC, tetD, tetE and tetG [20];dfrA1, dfrA9 
[21];dfrA12, dfrA13, dfrA7, dfrA17 [22]
Ahmed et al. Annals of Clinical Microbiology and Antimicrobials 2010, 9:12
http://www.ann-clinmicrob.com/content/9/1/12
Page 4 of 7isolates were from livery premises. The resistance profiles
of the MDR isolates fell mostly into three distinct groups:
AMP, CHL, TET, TRI, NAL (n = 27/23.4%); AMP,
CHLTET, TRI (n = 21/18.2%); AMP, TET, TRI, NAL (n =
9/7.8%).
Antimicrobial resistance genes
In total, nine resistance genes were identified (Table 3).
Trimethoprim resistance was attributable to dfr genes in
93% (260/279) at the following frequencies: dfr1 (40.3%),
dfr17 (28%), dfr12 (17.3%) and dfr9 (0.3%). Of the tetracy-
cline resistant isolates, 86.8% (172/198) were positive by
PCR for tet genes, with tetB the most prevalent gene
(71%), followed by tetA at 18% and tet(A+B) at 11%.
Amplicons of the catI gene were obtained from 73.5%
(75/102) of chloramphenicol resistant isolates, all of
which were of hospital origin. Only one of these was also
resistant to florfenicol. Of the ampicillin resistant iso-
lates, the TEM β-lactamase genes was identified in 91%
(174/191) and only one isolate was positive for the SHV
β-lactamase genes.
Conjugation experiments
Eight transconjugants (8/35) were obtained, and all were
from hospital isolates (Table 4). The resistance profiles of
the transconjugants were re-confirmed by disc diffusion
testing and found to be identical to those of the donors.
The resistance phenotype AMP, CHL, TET, TRI was the
dominant (n = 6) followed by AMP, TET, TRI (n = 2).
Discussion
Our results show that hospitalized horses are more likely
to shed antibiotic resistant E. coli strains, and their faeces
are more likely to harbour MDR than those of horses in
livery premises. The significantly higher prevalence of
antibiotic resistance and of MDR found in hospitalized
horses in this study fits well with previous observations
[23]. All the horses at the PLEH are referrals from private
veterinary practices, so many of the horses will have
undergone treatment, which may include prior antibiotic
administration. Thus, the higher prevalence of resistant
E. coli in hospitalized horses could reflect conditions
prior to arrival at the PLEH. Transportation and other
stress factors have also been shown to increase the shed-
ding of antibiotic resistant enteric bacteria [23], and this
may also have influenced the prevalence of resistant E.
coli strains in samples collected from the PLEH.
Ampicillin resistance in E. coli isolates described in this
paper was largely associated with TEM β-lactamase
genes, with only one isolate positive for SHV β-lactamase
genes. This agrees with other reports that TEM β-lacta-
mase genes (i.e. TEM-1 β-lactamase gene) are the most
prevalent in ampicillin resistant E. coli of animal origin,
as well as being commonly reported in human E. coli iso-
lates of hospital origin [23]. Furthermore, this study iden-
tified 17 isolates as resistant to cephalosporins (i.e.
potential ESBL producers), all of which were positive for
TEM β-lactamase genes, with MICs for ampicillin ≥ 256
μg/ml (except for two isolates against, which the MICs =
128 μg/ml). The prevalence of extended spectrum beta-
lactamase (ESBL) resistance in European countries of E.
coli human isolates is reported to be around 3.9% [24]
with variations between countries. ESBL-targeted drugs
are being used more frequently, but may result in muta-
tions of TEM and SHVβ-lactamase genes, as well as the
widely prevalent ctx-m types [25]. For the potential ESBL
producers more identification and confirmation is
Table 2: Resistance profiles and MDR frequency in E. coli isolates from equine faecal samples.
Abs No. of faecal samples 
with at least one 
resistant E. coli; disc 
diffusion method (%)
No E. coli isolates 
exhibiting resistant 
phenotype
Proportion of isolates 
resistant by disc 
diffusion method, 
which were 
confirmed by MIC
No MDR-positive 
faecal samples
(% faecal samples)
AMP 89 (33.7%) 191 93.0% 57 (21.6%)
APR 1 (0.4%) 1 - 1 (0.4%)
NAL 36 (13.6%) 72 - 35 (13.3%)
CIP 28 (10.6%) 65 93.8% 28 (10.6%)
CHL 49 (18.6%) 102 100% 47 (17.8%)
FLO 9 (3.4%) 14 - 9 (3.4%)
TET 92 (34.8%) 198 93.4% 57 (21.6%)
TRI 135 (51.0%) 279 95.0% 57 (21.6%)
Abbreviation: ABs, antimicrobials; AMP, ampicillin; APR, apramycin; NAL, nalidixic acid; CIP, ciprofloxacin; CHL, chloramphenicol; FLO, 
florfenicol; TET, tetracyclin; TRI, trimethoprim
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results showed that E. coli resistance genes from horses
are similar to those found in other animals and humans,
however these need further investigation, specifically by
sequencing the TEMβ-lactamase PCR products.
In our study, the tetB gene was the most prevalent
(71%) tetracycline resistance gene, followed by tetA
(18%), and no other tet gene was identified. This preva-
lence pattern has also been reported in E. coli strains
from various animals, including horses [26]. The tetB
gene has the widest host range among gram-negative
pathogens [27]. In gram-negative bacteria, tetA and tetB
efflux genes are widely distributed and normally associ-
ated with plasmids, of which most are conjugative [27]
and there is evidence for a correlation between the wide-
spread distribution of tetracycline resistance genes and
the sub-therapeutic antimicrobial use of tetracycline [28].
However, in the UK, tetracyclines are used relatively
rarely in equine veterinary medicine, suggesting that the
tet resistance genes identified here may have been
acquired by co-selection mechanisms, as discussed
below.
The catI gene, responsible for most of the plasmid-
mediated resistance to chloramphenicol, was the only cat
gene detected in the chloramphenicol resistant isolates.
Most of chloramphenicol resistant isolates (47/102) were
of the MDR phenotype (Table 2), suggesting that resis-
tance to chloramphenicol is likely to be part of a multiple
resistance system. The non-enzymatic chloramphenicol
resistance gene (cmlA) also confers resistance to florfeni-
col. However, that cmlA gene was not identified by PCR,
suggesting that the observed flofenicol resistance was
possibly due to flo gene, although some chloramphenicol
resistant genes can also be responsible for flofenicol resis-
tance [29]. The use of chloramphenicol in UK veterinary
medicine is generally restricted to topical application as a
treatment for ophthalmic conditions, and is hardly ever
used systemically. Chloramphenicol resistance was
almost exclusively found in hospital-derived samples
indicating that, as with tetracycline resistance, chloram-
Table 3: Summary of results showing the identification and distribution of antibiotic resistance genes in E. coli isolates 
from equine faecal samples taken from hospital and livery premises.
Antibiotic(No. of 
resistant
isolates investigated)
Source and 
number(N) of isolates
Identified by PCR Not identified by
PCR
Antibiotic resistance 
gene composition 
tested by PCR (details 
in table legend)
AMP (191) Hospital n = 177
Livery n = 14
169
5
8
9
TEM & SHV β-
lactamase genes
CHL (102) Hospital n = 97
Livery n = 5
75
0
22
5
catI catII catIII cmlA
TET (198) Hospital n = 177
Livery n = 21
154
18
23
3
tetB tetA tetC tetD tetE 
tetG
TRI (279) Hospital n = 209
Livery n = 70
195
65
14
5
dfrA1 dfrA17 dfrA12 
dfrA9 dfrA7, dfrA13
All genes listed were tested by PCR amplification using gene-specific primer pairs listed in Table 1. Genes positively identified by PCR are 
shown in bold, and are listed according to their frequency of occurrence within each resistance group: AMP, TEM lactamase genes 91%, 
SHV β-lactamase genes 0.6%; CHL, catI 73.5%; TET, tetB 71%, tetA 18%,tetA+B 11%; TRI, dfrA1 40.3%, dfrA17 28%, dfrA12 17.3%, dfrA9 
0.3%. Those genes failed to give rise to detectable levels of PCR product are listed in normal type.
Abbreviations: AMP, ampicillin; CHL, chloramphenicol; TET, tetracycline; TRI, trimethoprim
Table 4: Resistant isolates that transferred resistance via 
conjugation, listed according to their resistance 
phenotypes.
Antibiogram Donor genes contributing to the 
phenotype of each isolate
AMP, CHL, TET, TRI (n = 6) dfrA17, tetA, catI,TEM β-lactamase 
genes
dfrA17, catI,TEM β-lactamase genes
tetA, dfr1, dfrA17,TEM β-lactamase 
genes
dfrA17, dfrA12, tetB,TEM β-lactamase 
genes
dfrA12, tetA, tetB,TEM β-lactamase 
genes, catI
dfrA1, dfrA1, tetB,TEM β-lactamase 
genes, catI
AMP, TET, TRI (n = 2) dfrA17, dfrA12, tetB,TEM β-lactamase 
genes
dfrA1, tetB,TEM β-lactamase genes
Abbreviations: AMP, ampicillin; CHL, chloramphenicol; TET, 
tetracycline; TRI, trimethoprim; n = number of isolates
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via linked trimethoprim and ampicillin resistance genes.
A large proportion (93%) of the trimethoprim resistant
isolates were positive for at least one of the dfr genes, that
are commonly encoded on mobile genetic elements. Par-
ticularly, dfrA1 has spread rapidly on the transposon Tn7
to become the most prevalent gene responsible for
trimethoprim resistance in the UK [30], and the most
prevalent in our study, followed by dfrA12 and dfrA17.
The dfrA9 was found only in one isolate in the present
study. The dfrA9 gene, first reported in porcine E. coli
strains, has also been reported in veterinary isolates and
spread to human strains probably as a consequence of the
extensive use of potentiated sulphonamide products (e.g.
Sulfadiazine/trimethoprim) in veterinary medicine [31].
Reportedly, dfr genes are mostly conjugally transferable
[6,32].
A previous study on horses has documented in vitro
conjugal transfer of antibiotic resistant genes between
genera of Enterobacteriaceae [12]. In studies on E. coli
isolates of human origin, the wide dissemination of
dfrA17 in urinary E. coli isolates is due mainly to the hor-
izontal transfer of class 1 integrons, via conjugative plas-
mids [32]. Similarly, horizontal transfer through
conjugative plasmids has been reported to be responsible
for the wide dissemination of mobile genetic elements
(e.g. class 1 integrons) in E. coli isolates from humans and
animals [6]. Classes of integrons are widely reported in
Enterobacteriaceae from animals [6,10] and in E. coli of
animal origin, including horses [1]. Some of our isolates
possess the ability to transfer resistance to a recipient (E.
coli K12), see table 4, clearly indicating that the resistance
is harboured on mobile genetic elements.
Our MIC determination and genetic analysis of resis-
tant isolates suggests that in horses, antibiotic resistance
is conferred by the same E. coli resistance genes found in
other animal species. In total, 115/296 (38.8%) of our iso-
lates showed MDR. Interestingly, MDR transferred in the
conjugation studies, in which all transconjugants showed
resistance to ampicillin and trimethoprim (table 4), indi-
cating that both resistance profiles are encoded on
mobile genetic elements. Antibiotic resistance can arise
in the absence of selective pressures where antibiotic
resistance genes are linked on a mobile genetic element;
in these cases, exposure to a single antimicrobial agent
has been shown to give rise to co-selection of multiple
antibiotic resistance genes. Furthermore, stopping treat-
ment, and consequent removal of selective pressure, does
not necessarily lead to the loss of resistance [4,33]. Resis-
tance to a range of antimicrobials can thus be selected for
by administrating one, or a subset, of antimicrobials [9].
The shedding of resistant bacteria could thus produce a
reservoir of resistant bacteria in the environment [4,10].
This type of mechanism may account for the presence of
genes conferring resistance to tetracyclines and chloram-
phenicol, which are very rarely used therapeutically in
equine veterinary medicine in the UK. Further work is
required to define the multidrug resistant mechanisms,
that may be responsible for the high level of prevalence of
the resistance profiles (AMP, CHL, TET, TRI, NAL; AMP,
CHL, TET, TRI; AMP, TET, TRI, NAL) we have identi-
fied. That most of these were from hospital sources might
explain the possible role of antimicrobials in the dissemi-
nation and development of resistance in this environ-
ment.
Conclusions
To our knowledge this is the first study of antibiotic resis-
tant E. coli in equine faeces in the UK. Many of the genes
we have identified as responsible for antibiotic resistance
in equine E. coli are commonly found in other domestic
animals and humans. Antibiotic resistance found in
horses probably originates from, and is selected by, the
same sources and mechanisms as in other animal species.
Thus, in the UK, horses may be both recipients, and
sources of the zoonotic transmission of antibiotic resis-
tance and MDR, as well as providing an extensive reser-
voir for antimicrobial resistance genes.
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